Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00665002 · ClinicalTrials.gov registry record · NA
Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms
A NA study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- NA
- Development phase
- 16
- Enrollment target
NCT00665002 is a NA study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 16 participants.
The verdict
NCT00665002, a NA study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the WT-1 vaccine causes an immune response and is safe. The WT-1 vaccine is made up of protein pieces that the patient's immune system can recognize as abnormal.
Interventions
- DRUG Sargramostim (GM-CSF)
- BIOLOGICAL WT-1
- DRUG Montanide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2008-06 |
| Est. Completion | 2015-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00665002
The ClinicalTrials.gov registry entry for NCT00665002 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sargramostim (GM-CSF) is the first listed.
NCT00665002 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00665002 about?
NCT00665002 is a clinical study titled "Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms". The purpose of this study is to determine whether the WT-1 vaccine causes an immune response and is safe. The WT-1 vaccine is made up of protein pieces that the patient's immune system can recognize as abnormal.
What is the current status of trial NCT00665002?
This trial is currently completed. It is a NA study. The enrollment target is 16 participants. The study started on 2008-06. Estimated completion is 2015-02.
What interventions are being tested in trial NCT00665002?
The interventions under investigation include: Sargramostim (GM-CSF) (DRUG), WT-1 (BIOLOGICAL), Montanide (DRUG).
Who is sponsoring clinical trial NCT00665002?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.